Vivani jumps as US FDA lifts clinical hold on trial for diabetes treatment implant

Vivani Medical

13/06/2024 13:45

** Shares of implant maker Vivani Medical  VANI.O  rise
12.2% to $1.84 premarket 
    ** Co says the U.S. FDA has lifted clinical hold placed on
early-stage human trial evaluating its implant, NPM-119, for
treating type 2 diabetes 
    ** Says NPM-119 is being reviewed to potentially improve
tolerability issues associated with oral and injectable type 2
diabetes medications
    ** Up to last close, stock is up 59.8% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))